The sale of 23andMe has been finalized, transforming the once-public genetics company into a nonprofit under the leadership of its cofounder, Anne Wojcicki.
The deal—approved by U.S. Bankruptcy Judge Brian C. Walsh—marks the end of a months-long bidding war following 23andMe’s bankruptcy filing in March 2025.
TTAM Outbids Regeneron in $305 Million Deal
Biotech firm Regeneron Pharmaceuticals had previously bid $265 million to acquire the company in May. Still, it was outmatched by the TTAM Research Institute, a nonprofit founded by Wojcicki, which secured the deal with a $305 million offer.
“I am incredibly excited and humbled to share with you that TTAM…has completed the acquisition of 23andMe,” Wojcicki announced on X (formerly Twitter). “A nonprofit structure is the best way to solidify our values and commitments to our customers, the scientific community and the world at large.”
Despite the optimism, multiple U.S. states, including California, Utah, Tennessee, and Texas, opposed the sale, citing unresolved privacy concerns.
